Literature DB >> 3924605

Protection against fatal Pseudomonas aeruginosa sepsis by immunization with smooth and rough lipopolysaccharides.

S J Cryz, P M Meadow, E Fürer, R Germanier.   

Abstract

The protective capacity of various native and mutant lipopolysaccharide antigens against fatal Pseudomonas aeruginosa burn wound sepsis was evaluated. Immunization with O-polysaccharide-deficient lipopolysaccharides derived from Escherichia coli J5 or Salmonella typhi Ty 21a afforded substantial protection against only one of five Pseudomonas aeruginosa challenge strains of various serotypes. Immunization with both lipopolysaccharide antigens evoked antibody of the immunoglobulin G class which recognized lipopolysaccharide isolated from the challenge strain against which protection was noted. This was not seen for the remaining four challenge strains. Attempts to demonstrate cross-serotype protection using O-antigen-deficient and core-deficient Pseudomonas aeruginosa lipopolysaccharide antigens was, for the most part, unsuccessful. In contrast, high levels of protection against all six serotypes of challenge strains were seen following immunization with homologous lipopolysaccharide.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3924605     DOI: 10.1007/bf02013594

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  26 in total

1.  Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine.

Authors:  R Germanier; E Füer
Journal:  J Infect Dis       Date:  1975-05       Impact factor: 5.226

2.  Structure of the Core oligosaccharide from the lipopolysaccharide of Pseudomonas aeruginosa PAC1R and its defective mutants.

Authors:  P S Rowe; P M Meadow
Journal:  Eur J Biochem       Date:  1983-05-02

3.  Type-specific immunity in pseudomonas diseases.

Authors:  J G Crowder; M W Fisher; A White
Journal:  J Lab Clin Med       Date:  1972-01

4.  Pseudomonas bacteremia. Review of 108 cases.

Authors:  M R Flick; L E Cluff
Journal:  Am J Med       Date:  1976-04       Impact factor: 4.965

5.  Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: description of a burned mouse model.

Authors:  D D Stieritz; I A Holder
Journal:  J Infect Dis       Date:  1975-06       Impact factor: 5.226

6.  Protection against fatal Pseudomonas aeruginosa burn wound sepsis by immunization with lipopolysaccharide and high-molecular-weight polysaccharide.

Authors:  S J Cryz; E Fürer; R Germanier
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

7.  Experimental pneumonia due to Pseudomonas aeruginosa in leukopenic dogs: prolongation of survival by combined treatment with passive antibody to Pseudomonas and granulocyte transfusions.

Authors:  J A Kazmierowski; H Y Reynolds; J C Kauffman; W A Durbin; R G Graw; H B Devlin
Journal:  J Infect Dis       Date:  1977-03       Impact factor: 5.226

8.  The isolation and characterization of lipopolysaccharide-defective mutants of Pseudomonas aeruginosa PAC1.

Authors:  S F Koval; P M Meadow
Journal:  J Gen Microbiol       Date:  1977-02

9.  Active immunization with lipopolysaccharide Pseudomonas antigen for chronic Pseudomonas bronchopneumonia in guinea pigs.

Authors:  J E Pennington; W F Hickey; L L Blackwood; M A Arnaut
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

Review 10.  Analysis of 1,186 episodes of gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy.

Authors:  C S Bryan; K L Reynolds; E R Brenner
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug
View more
  2 in total

1.  Smooth lipopolysaccharide is the major protective antigen for mice in the surface extract from IATS serotype 6 contributing to the polyvalent Pseudomonas aeruginosa vaccine PEV.

Authors:  S MacIntyre; R Lucken; P Owen
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

2.  Outer membrane protein F preparation of Pseudomonas aeruginosa as a vaccine against chronic pulmonary infection with heterologous immunotype strains in a rat model.

Authors:  H E Gilleland; L B Gilleland; J M Matthews-Greer
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.